INTRODUCTION
============

Ischemic heart disease is now the leading cause of global mortality, accounting for 1.4 million deaths in developed countries and 5.7 million deaths in developing regions annually.^[@R1]^ Atrial fibrillation (AF) is the most common cardiac arrhythmia, and the global burden of AF is increasing with an estimated 33.5 million individuals worldwide affected by the condition in 2010.^[@R2]^ The age-adjusted prevalence rates in men and women have increased from 569.5 and 359.9/100,000 persons, respectively, in 1990 to 592.2 and 373.1, respectively, in 2010 with mortality increasing by 2-fold over that time period.^[@R2]^ Age is a major risk factor for AF, and the likelihood of being diagnosed with AF after age 55 increases by approximately 2-fold over 10 years.^[@R2],[@R3]^ Other risk factors for AF include obesity, cardiovascular complications, and a history of smoking and alcohol use.^[@R4]^

The American College of Cardiology/American Heart Association/Heart Rhythm Society guidelines categorize AF on the basis of cause.^[@R5]^ AF that is not attributable to heart valve defects is considered nonrheumatic AF (NRAF), whereas secondary AF is attributable to other conditions, such as pulmonary or cardiac disease. The occurrence of AF in a patient \<60 years with no evidence of cardiac or pulmonary dysfunction has historically been diagnosed as lone AF.^[@R5]^

AF is associated with thromboembolic events, including stroke, and a seminal analysis by the Framingham Heart Study showed that the risk of stroke in the presence of AF increases significantly with age.^[@R6]^ To prevent embolism and stroke, patients with AF are typically treated with an anticoagulant and/or antiplatelet therapy. Warfarin, one of the most prescribed anticoagulants, has been tested in both fixed and adjusted doses.^[@R7]^ In recent years, alternative anticoagulants such as factor X and thrombin inhibitors have also been approved for use in patients with AF.^[@R8]^ Antiplatelet therapies including aspirin and clopidogrel are currently prescribed both alone and in combination with an anticoagulant.^[@R5]^

Anticoagulants are thought to be more effective than antiplatelet agents (mainly aspirin) at reducing stroke, as well as systemic embolism risk in patients with AF.^[@R9],[@R10]^ However, hemorrhage and bleeding have been linked to the use of both.^[@R5]^ Therefore, achieving an optimal balance between the risk of stroke and bleeding is crucial for the individual management of AF. Data generated by trials comparing a placebo with an anticoagulant or an antiplatelet agent may not address this issue. To remedy this problem, several randomized trials have compared the effects of treatment with an anticoagulant with those of an antiplatelet therapy; however, recent meta-analyses of these trials are lacking. The importance of this topic warrants an update to the existing literature; therefore, the objective of the present study was to conduct a meta-analysis of randomized trials comparing the safety and efficacy of anticoagulant and antiplatelet therapies for patients with AF. We focused our analysis on those studies comparing adjusted-dose anticoagulants with antiplatelet therapy.

METHODS
=======

Search Strategy
---------------

The methods used in this review adhere to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. MEDLINE, Cochrane, EMBASE, and Google Scholar databases were searched using combinations of the following terms: anticoagulants, antiplatelet, AF, warfarin, aspirin, stroke, and systemic embolism. The search was performed for studies published through May 31, 2014. The reference lists of relevant studies were hand searched to identify other studies that met the inclusion criteria. After the preliminary search results were obtained, duplicate citations were eliminated. The remaining citations were screened by a 2-step process to identify the final studies that would be included in the meta-analysis. In the first step, the title and abstract of each article were examined, and citations not meeting the inclusion criteria were discarded. In the second step, we obtained full-text copies of the remaining citations, and these were examined to determine which met all of the inclusion criteria. Studies were identified by the search strategy by 2 independent reviewers. If any uncertainties existed regarding eligibility, a third reviewer was consulted. Ethical approval of this study was waived, as meta-analyses do not involve patients.

Selection of Studies
--------------------

Criteria for inclusion in the meta-analysis were randomized controlled trial, diagnosis was AF, interventions involved anticoagulants (warfarin) and antiplatelet therapy, anticoagulants and antiplatelet therapy were administered alone and not combined with the other treatments, and outcomes of anticoagulants and antiplatelet therapy were compared. Exclusion criteria were as follows: the intervention was for secondary prevention, and not primary prevention of stroke or thromboembolic events; outcomes of interest were not reported; the study was nonrandomized. Non-English and non-Chinese publications, letters, case reports, comments, and editorials were also excluded.

Data Extraction
---------------

Data were extracted from eligible studies by 2 reviewers. Any disagreements between the 2 reviewers were resolved by consulting a third reviewer. The following information/data were extracted from studies that met the eligibility criteria: the name of the first author, year of publication, study design, number of participants in each treatment group, mean age and gender of participants in each group, diagnostic criteria, drug and dosage for each study group, and data regarding the outcome measures listed below.

Outcome Measures
----------------

The primary outcomes were the rates of stroke. The secondary outcomes were the rates of systemic embolism and hemorrhage/major bleeding. Stroke (ischemic or hemorrhagic) was defined as acute onset of a focal neurological deficit of presumed vascular origin lasting for 24 hours or more. The events included minor, nondisabling, disabling, or fatal strokes. Systemic arterial embolism was defined as thromboembolic complications in the extremities, kidneys, mesenteric arteries, lungs, spleen, retina, or grafts there were verified using imaging studies, surgery, or autopsy. Systemic arterial embolism did not include myocardial infarction. Major hemorrhage was defined as an intracranial hemorrhage (including hemorrhagic stroke) or extracranial bleeding that was fatal or required a transfusion, surgery, or hospital admission. Hemorrhagic stroke was included as stroke and also as major hemorrhage.

Statistical Analysis
--------------------

The differences in the rates of hemorrhage/major bleeding, stroke, and embolism were compared between participants receiving either anticoagulant or antiplatelet therapy. Odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated for binary outcomes, and were compared between treatments. A separate subgroup analysis was performed to determine the effects of treatments on patients with NRAF. In this meta-analysis, the OR indicates the risk of events (ie, stroke, embolism, and bleeding) of anticoagulants relative to antiplatelet treatment (Risk~anticoagulant~/Risk~antiplatelet~). Thus, an OR \> 1 indicates more events with anticoagulants and an OR \< 1 indicates less events with anticoagulants. For example, an OR \> 1 indicates a greater risk of a stroke with anticoagulants relative to antiplatelet therapy, and an OR \< 1 indicates a lower risk of stroke with anticoagulants relative to antiplatelet therapy.

A χ^2^-based test of homogeneity was performed by using Cochran *Q* statistic and *I*^2^. *I*^2^ illustrates the percentage of the total variability in effect estimates among trials that is due to heterogeneity rather than to chance. Random-effects models were used if heterogeneity was detected (*I*^2^ \> 50%). Otherwise, fixed-effects models were used. Pooled ORs were calculated, and a 2-sided *P* value \<0.05 was considered statistically significant. Sensitivity analysis was performed using the leave-one-out approach, and publication bias was assessed by constructing a funnel plot for the rate of stroke and by Egger test. The absence of publication bias is indicated by the data points forming a symmetric, funnel-shaped distribution and by a 1-tailed significance level of *P* \> 0.05 in Egger test.

All analyses were performed with Comprehensive Meta-Analysis statistical software, version 2.0 (Biostat, Englewood, NJ).

Quality Assessment
------------------

Quality of the included studies was assessed using the 'Risk of Bias' tool in Review Manager 5.3 (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) and by constructing a funnel plot. Recommendations for judging risk of bias are provided in Chapter 8 of the *Cochrane Handbook for Systematic Reviews of Interventions*.^[@R11]^

RESULTS
=======

Study Selection
---------------

A flow diagram of study selection is shown in Figure [1](#F1){ref-type="fig"}. A total of 288 articles were identified in the initial search. Of these, 24 (8.33%) underwent full-text review and 15 were excluded; 11 studies did not report an intervention of interest,^[@R12]--[@R22]^ 3 did not study patients of interest,^[@R23]--[@R25]^ and 1 did not report an outcome of interest.^[@R26]^ Thus, 9 articles met the inclusion criteria and were included in the analysis.^[@R7],[@R27]--[@R34]^ Two of the articles report findings of the Stroke Prevention in AF II study.^[@R31],[@R32]^ However, because each article presented unique data, both were included in the meta-analysis. (Thus, the analysis included data of 8 studies and 9 articles.)

![The Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram for study selection.](medi-94-e409-g001){#F1}

Study Characteristics
---------------------

Characteristics of the 8 trials are summarized in Tables [1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. With the exception of the studies by Lavitola et al^[@R27]^ and Hu et al,^[@R34]^ participants in the studies were \>70 years of age, and the ages of the participants were generally similar between the treatment arms. The number of participants in the anticoagulant treatment arms ranged from 36 to 555 (n = 2169), whereas the number in the antiplatelet treatment arms ranged from 39 to 545 (n = 2194). Warfarin was used in all of the studies except for that of Hellemons et al^[@R30]^ that used coumarin, and in all studies the antiplatelet treatment was aspirin. The doses of anticoagulant were titrated to an international normalized ratio (INR) of 2.0 to 4.5, and aspirin was administered at a dosage of 75 to 325 mg/d.

###### 

Baseline Characteristics of Trials Included in the Meta-Analysis

![](medi-94-e409-g002)

###### 

Clinical Events of Patients Treated With an Anticoagulant or Aspirin

![](medi-94-e409-g003)

Quality Assessment
------------------

Results of the quality assessment of the 8 trials are shown in Figure [2](#F2){ref-type="fig"}. Only 2 trials^[@R6],[@R19]^ were unbiased in 7 of 7 categories, whereas several had a high risk of performance or detection bias.

![Quality assessment of each included study. (A) Risk of bias summary. (B) Risk of bias graph. AFASAK = the Copenhagen atrial fibrillation, aspirin and anticoagulation study, BAFTA = Birmingham atrial fibrillation treatment of the aged study, PATAF = primary prevention of arterial thromboembolism in nonrheumatic atrial ibrillation study, SPAF = stroke prevention in atrial fibrillation II study, WASPO = warfarin vs aspirin for stroke prevention in octogenarians study.](medi-94-e409-g004){#F2}

Outcomes
--------

### Stroke

In the 8 trials, 90 patients receiving an anticoagulant and 136 receiving aspirin experienced a stroke. Since the Warfarin vs Aspirin for Stroke Prevention in Octogenarians (WASPO) study reported a stroke rate of 0% for both groups, only 7 studies were included in the analysis. A random-effects analysis was applied because there was evidence of heterogeneity among the studies (*Q* statistic = 12.885, *I*^2^ = 53.43%, *P* = 0.04). Subgroup analysis of patients with NRAF used a fixed-effects model because no evidence of heterogeneity was noted (*Q* statistic = 5.212, *I*^2^ = 4.08%, *P* = 0.39). In the overall analysis, there was no significant difference in the stroke rate between the groups (OR = 0.667, 95% CI 0.426--1.045, *P* = 0.08) (Figure [3](#F3){ref-type="fig"}A). In contrast, subgroup analysis revealed that patients with NRAF who were treated with an anticoagulant had a lower risk of stroke (OR = 0.557, 95% CI 0.411--0.753, *P* \< 0.001).

![A forest plot comparing the rates of stroke (A), systemic embolism (B), and hemorrhage/major bleeding (C) for participants receiving treatment with an anticoagulant or antiplatelet therapy. AF = atrial fibrillation, AFASK = Copenhagen atrial fibrillation, aspirin and anticoagulation study, BAFTA = Birmingham atrial fibrillation treatment of the aged study, CI = confidence interval, Lower limit = lower bound of the 95% CI, NRAF = nonrheumatic AF, OR = odds ratio, PATAF = primary prevention of arterial thromboembolism in nonrheumatic atrial fibrillation study, SPAF = stroke prevention in atrial fibrillation II study, Upper limit = upper bound of the 95% CI.](medi-94-e409-g005){#F3}

### Systemic Embolism

In the 8 trials, 32 patients receiving an anticoagulant and 58 receiving aspirin experienced an embolism. Since the WASPO study reported a rate of 0% for both groups, only 7 studies were included in the analysis. A fixed-effects analysis was applied because there was no evidence of heterogeneity (all studies: *Q* statistic = 3.915, *I*^2^ = 0.0%, *P* = 0.69; studies of NRAF patients: *Q* statistic = 3.471, *I*^2^ = 0.0%, *P* = 0.63). For all studies, treatment with anticoagulants was associated with a lower risk of embolism (OR = 0.616, 95% CI = 0.392--0.966, *P* = 0.04) (Figure [3](#F3){ref-type="fig"}B). Subgroup analysis showed that in patients with NRAF, anticoagulants were associated with a lower risk of embolism (OR = 0.581, 95% CI 0.359--0.941, *P* = 0.03).

### Hemorrhage/Major Bleeding

In the 8 trials, 135 patients receiving an anticoagulant and 83 receiving aspirin experienced a hemorrhage or major bleeding. A random-effects analysis was applied because of heterogeneity among the studies (all studies: *Q* statistic = 25.703, *I*^2^ = 72.77%, *P* = 0.001; studies of NRAF patients: *Q* statistic = 20.809, *I*^2^ = 7 5.97%, *P* = 0.001; studies of patients with AF: *Q* statistic = 3.351, *I*^2^ = 71.16%, *P* = 0.07). No significant difference in the rate of hemorrhage/major bleeding was noted when all 8 studies were analyzed (OR = 1.497, 95% CI 0.730--3.070, *P* = 0.27), for patients with NRAF (OR = 1.542, 95% CI 0.626--3.798, *P* = 0.35), or for patients with AF (OR = 0.883, 95% CI 0.060--13.026, *P* = 0.93) (Figure [3](#F3){ref-type="fig"}C).

Sensitivity Analysis
--------------------

Results of the sensitivity analysis using the leave-one-out approach are shown in Figure [4](#F4){ref-type="fig"}. The results showed that the direction and magnitude of the combined estimates did not change markedly with the exclusion of individual studies indicating the meta-analysis has good reliability.

![Sensitivity analysis showing the influence of each study on the pooled estimate for the rate of stroke using the leave-one-out approach. CI = confidence interval, Lower limit = lower bound of the 95% CI, OR = odds ratio, Upper limit = upper bound of the 95% CI.](medi-94-e409-g006){#F4}

Publication Bias
----------------

Results of the assessment of publication bias are shown in Figure [5](#F5){ref-type="fig"}. The individual data points formed a symmetrical, funnel-shaped distribution indicating the absence of publication bias. Egger test confirmed no publication bias (*t* = 0.32, 1-tailed *P* = 0.38).

![A funnel plot of the rates of stroke of the included studies. OR = odds ratio.](medi-94-e409-g007){#F5}

DISCUSSION
==========

In this meta-analysis, we compared the efficacy and safety of anticoagulant treatment with aspirin antiplatelet therapy in patients with AF. A total of 8 studies with approximately 4300 patients were included in the analysis. By including recently published trials, this analysis provides a crucial update to the field. The results suggest that anticoagulants are more effective than aspirin in preventing embolisms in patients with AF. Although overall the risk of stroke was similar between treatments, in patients with NRAF anticoagulants were associated with a lower risk of stroke. Importantly, the overall and subgroup analyses showed that there was no difference in bleeding events between patients treated with anticoagulants and aspirin.

AF is the most common sustained cardiac arrhythmia and an independent risk factor for stroke; in patients with AF the risk of stroke is 2 to 17 times that of the general population.^[@R2],[@R4],[@R5]^ Despite its increasing prevalence, the pathophysiological mechanisms leading to AT are only recently being described. The majority of cases of AF are associated with heart disease including coronary artery disease, congestive heart failure, valvular heart disease, and hypertension.^[@R35]^ Other conditions associated with AF include hyperthyroidism, excessive alcohol consumption, obesity, and sleep apnea.^[@R35]^ Pathophysiological mechanisms thought to be responsible for AF include abnormalities of intracellular calcium signaling^[@R36]^ and atrial remodeling.^[@R35],[@R37]^ Age-related changes including vascular stiffening and cardiac remodeling are thought to be responsible for the association of AF with aging, and approximately 25% of strokes in persons \>80 years of age are due to AF.^[@R3]^ Genetic factors are being increasing recognized as having a role in the development of AF,^[@R35]^ as is the role of microRNAs, small noncoding RNAs that are important regulators of gene expression.^[@R38]^ Polymorphisms in glycoprotein IIb/IIIa, which participates in clotting by binding to fibrinogen and von Willebrand factor, have been shown to increase the risk of stroke.^[@R39]^

Despite the fact that adjusted-dose anticoagulants are difficult to use and many patients do not maintain a therapeutic INR, current guidelines recommend that most patients with AF receive anticoagulation.^[@R5]^ Our results confirm the validity of this recommendation only for patients with NRAF, because they indicate that the use of an anticoagulant may reduce the risk of stroke and embolism whereas producing no greater risk of hemorrhage or bleeding. Moreover, they suggest that treatment with an anticoagulant may be more suitable than antiplatelet therapy for patients with nonvalvular AF and a CHA~2~DS~2~-VASc score of 1, for whom current guidelines recommend either an anticoagulant or antiplatelet therapy.^[@R5]^

Other meta-analyses have compared the safety and efficacy of anticoagulants with those of antiplatelet therapies.^[@R9],[@R10],[@R40]--[@R42]^ Saxena and Koudstaal^[@R9]^ focused on secondary prevention and included only 2 studies. Three meta-analyses^[@R10],[@R40],[@R42]^ concluded that anticoagulants were associated with a lower risk of stroke as compared with antiplatelet therapy. Two studies^[@R40],[@R41]^ concluded that anticoagulants were superior to antiplatelet therapy for preventing a systemic embolism. Two studies that reported data on major bleeding or hemorrhage^[@R10],[@R41]^ did not find substantial evidence for increased risk of these events with the use of anticoagulants compared with antiplatelet therapy.

Several reasons may account for the observed differences between these studies and our own regarding the superior ability of anticoagulants to prevent stroke in NRAF patients. First, different studies were included in the analyses. Segal et al^[@R10]^ only included the Copenhagen Atrial Fibrillation, Aspirin and Anticoagulation study (AFASAK) I and II and the Stroke Prevention in Atrial Fibrillation II (SPAF II) studies, all of which enrolled patients with NRAF. Therefore, their findings agree with our own subgroup analysis. Seven of 8 studies included in our analysis (the Birmingham Atrial Fibrillation Treatment of the Aged study (BAFTA), Primary Prevention of Arterial Thromboembolism in Nonrheumatic Atrial Fibrillation, AFASAK I and II, Chinese Antithrombotic Therapy in Atrial Fibrillation Study, WASPO, and SPAF II) were also included in the analysis by Hart et al.^[@R42]^ However, their analysis included the EAFT study,^[@R43]^ which assessed secondary prevention in patients with NRAF (N = 455), but not that of Lavitola et al,^[@R27]^ which enrolled patients with rheumatic mitral valve disease (RMVD) (N = 229). Aguilar et al^[@R40]^ included the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE W) study, which used clopidogrel (N = 6706) in their analysis, but they did not include the BAFTA study (N = 973). In addition, Segal et al^[@R10]^ and Hart et al^[@R42]^ used the subgroup data from the SPAF II trial for patients older or \<75 years, whereas we did not.

It should also be noted that patients with nonvalvular AF and valvular AF are different populations and have a different risk for thromboembolism.^[@R5]^ In the study by Lavitola et al^[@R27]^ of patients with RMVD, there were 15 embolic events in patients receiving aspirin and 24 in patients receiving warfarin; however, 21 of the patients receiving warfarin had an INR \< 2.0 and only 3 had an INR from 2.0 to 2.2 at the time of the event. When the current meta-analysis is performed with exclusion of the Lavitola et al study, the results (OR = 0.556, 95% CI 0.407--0.761, *P* \< 0.001) are almost identical to that of subgroup analysis for NRAF (OR = 0.557, 95% CI 0.411--0.753, *P* \< 0.001).

There are a number of limitations of this meta-analysis that need to be considered when interpreting the results. The trials included in this analysis, as well as prior meta-analyses, may not have taken into account differences in the time-in-therapeutic-range of the INR. This feature of warfarin use has been shown to vary significantly among the sites of the ACTIVE W trial.^[@R44]^ The definition of stroke may have varied between studies. For example, Hart et al^[@R42]^ included intracranial hemorrhage in the primary outcome of "all strokes," whereas we defined stroke as the acute onset of a focal neurological deficit of presumed vascular origin lasting for 24 hours or more. The number of studies included in the current analysis was relatively small, and the earliest study was performed in 1989 and the latest in 2010, and various treatment regimens were used over this 2-decade period. This highlights the need for additional high-quality studies to address this issue. Patient characteristics of the included studies were not homogeneous, and all but 2 studies enrolled patients \>70 years of age, and thus, the results may not be applicable to younger age groups. Most of the included studies reported data that was analyzed on an intent-to-treat basis, and thus, the pooled effect estimates may have been underestimated.

The only antiplatelet that was studied was aspirin, and newer antiplatelet drugs are available and their effectiveness compared with anticoagulation has yet to be determined. Lastly, several of the studies included in the analysis were found to have a high risk of performance or detection bias.

CONCLUSIONS
===========

The results of this meta-analysis suggest that anticoagulants are more effective than aspirin in preventing embolisms in patients with AF, and though the overall risk of stroke was similar between treatments, and in patients with NRAF anticoagulants were associated with a lower risk of stroke. No difference in bleeding events was found between patients treated with anticoagulants and aspirin. These results support the use of anticoagulation over aspirin to prevent thromboembolic events in patients with AF and illustrate that future trials should strive to enroll well-defined patient populations to allow a definitive analysis of how anticoagulants and antiplatelet therapies perform in different groups of patients.

Abbreviations: AF = atrial fibrillation, CI = confidence interval, INR = international normalized ratio, NRAF = nonrheumatic AF, OR = odds ratio, RMVD = rheumatic mitral valve disease.
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